UConn spin-off gets stem cell patent for autoimmune diseasesHartford BusinessImStem Biotechnology Inc. and the University of Connecticut today announced that a joint patent was recently issued for human embryonic stem cell technology being used by ImSt… Continue reading
UConn spin-off gets stem cell patent for autoimmune diseasesHartford BusinessImStem Biotechnology Inc. and the University of Connecticut today announced that a joint patent was recently issued for human embryonic stem cell technology being used by ImSt… Continue reading
EurekAlert (press release) |
Double agents: Vessels that help cancers spread can also boost immunotherapy
EurekAlert (press release) This process, lymphangiogenesis, also helps the tumor evade the patient’s own immune system, and it would be expected that inhibiting lymphangiogenesis, could enhance the efficacy of cancer immunotherapies, which are only effective in a minority of … Double agents: Vessels that help cancers spread can also boost immune therapiesMedical Xpress |
EurekAlert (press release) |
Double agents: Vessels that help cancers spread can also boost immunotherapy
EurekAlert (press release) This process, lymphangiogenesis, also helps the tumor evade the patient’s own immune system, and it would be expected that inhibiting lymphangiogenesis, could enhance the efficacy of cancer immunotherapies, which are only effective in a minority of … Lymph vessels that spread cancer can also help destroy tumoursBirmingham Mail |
|
Combination Immunotherapy Improves Kidney Cancer Survival
Newswise (press release) 12, 2017 – A combination immunotherapy treatment showed better overall survival in patients with previously untreated advanced or metastatic renal cell carcinoma than current therapy, according to results from a phase 3 clinical trial presented at the … |
Healio |
VIDEO: Gene alterations predict response to immunotherapy in urothelial carcinoma
Healio Alterations in DNA damage repair and response genes appear to improve response to immune checkpoint blockade among patients with urothelial carcinoma, according to findings presented at the ASCO Annual Meeting. These results “clearly” indicate that … |
Scientific American |
How Close Are We to a Lifelong Cure for Cancer?
Scientific American He developed methods to engineer a patient’s T cells into so-called chimeric antigen receptor T (CAR–T) cells, which recognize and kill a person’s unique cancer. This is called immunotherapy — training a person’s body to kill disease. One treatment … |
Myeloma Research News |
Poseida’s Myeloma-specific CAR T-cells Combat Aggressive Cancer in Mice, Study Shows
Myeloma Research News Poseida Therapeutics demonstrated that their new CAR T-cell treatment for multiple myeloma — P-BCMA-101 — possessed features that make it stand out in the field of gene-edited cancer cell therapies. The preclinical data, presented at the CAR-TCR … |